(MedPage Today) — The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck announced on Monday.
The long…
Source link : https://www.medpagetoday.com/pediatrics/rsv/115985
Author :
Publish date : 2025-06-09 21:31:00
Copyright for syndicated content belongs to the linked Source.
